about
Citrate anticoagulation: Are blood donors donating bone?Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange.Anticoagulation techniques in apheresis: from heparin to citrate and beyond.Comprehensive analysis of citrate effects during plateletpheresis in normal donors.Effects of anticoagulant on pH, ionized calcium concentration, and agonist-induced platelet aggregation in canine platelet-rich plasma.Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange.Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation.Complications of apheresis.Therapeutic plasma exchange: a technical and operational review.Mechanisms of adverse effects during hemapheresis.Membrane and centrifugal therapeutic plasma exchange: practical difficulties in anticoagulating the extracorporeal circuit.Comprehensive analysis of changes in clinically significant divalent serum cation levels during automated plateletpheresis in healthy donors in a tertiary care center in North India.National audit of citrate toxicity in plateletpheresis donors.Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation.A liquid calcium+vitamin D3 supplement is effective prophylaxis against hypocalcemic toxicity during apheresis platelet donation.Dietary citrate and plasma ionized calcium: Implications for platelet donors.Therapeutic plasma exchange performed in tandem with hemodialysis without supplemental calcium in the apheresis circuit.
P2860
Q30252024-1668F150-9531-4C87-8383-F57A3005DA49Q33340211-628CD21E-B809-4BCE-B72E-F0F2173121D1Q33400909-A2925C41-2583-418F-8328-27874D4A7F4BQ34090886-27E242D2-07F4-4F8C-9A5B-26E73CA8C7FDQ34199510-28EE3960-FD84-4267-9FB2-1C2D8EC60358Q34522399-6B830EB0-9AAF-4713-9456-0A01391AE592Q37231751-E64D040B-EB4F-4A89-9E97-479EDF4E00E2Q37982852-FA71DA19-C71D-46F6-9949-BB448DA9529FQ38082733-E9A67A0C-CFE1-438E-98D0-79CA57D8388AQ41208803-244604CE-6287-4B0A-8316-F746E98E2022Q42066793-95CF3660-E635-455B-BAF1-5DD53D466555Q42143141-C1A18A93-9621-498A-B6F9-30C6712A438DQ44033050-50074D6C-7110-420E-BDE9-C362EC7A750EQ44176230-A16DFD65-CA8C-4D6F-87B2-7DE968D73177Q48217959-9D3E57CE-488B-4A56-B4D3-BB64ACEF80EAQ48249170-BCFEC60F-5BAD-4898-A9D9-97EA2ED0F08EQ52869911-527703D1-C191-420B-A5CE-98176846C755
P2860
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Dosage regimens for citrate anticoagulants.
@en
Dosage regimens for citrate anticoagulants.
@nl
type
label
Dosage regimens for citrate anticoagulants.
@en
Dosage regimens for citrate anticoagulants.
@nl
prefLabel
Dosage regimens for citrate anticoagulants.
@en
Dosage regimens for citrate anticoagulants.
@nl
P2093
P356
P1476
Dosage regimens for citrate anticoagulants.
@en
P2093
McCullough J
Mishler JM
Szymanski IO
P304
P356
10.1002/JCA.2920010306
P577
1983-01-01T00:00:00Z